Impact of treatment modalities on survival of patients with locoregional esophageal squamous-cell carcinoma in Taiwan

Medicine (United States)

Volumn 95, Issue 10, 2016, Pages

  Chen, Hui Shan ^a   Hung, Wei Heng ^b   Ko, Jiunn Liang ^c,d   Hsu, Po Kuei ^e   Liu, Chia Chuan ^f   Wu, Shiao Chi ^a   Lin, Ching Hsiung ^b,g   Wang, Bing Yen ^b,c,h,i  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^g CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TAIWAN; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; TRENDS; TUMOR RECURRENCE;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN;

EID: 84962488642     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003018     Document Type: Article

References (55)

1. Chen MF, Yang YH, Lai CH, et al. Outcome of patients with esophageal cancer: A nationwide analysis. Ann Surg Oncol. 2013;20:3023-3030.
2. Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269-274.
3. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. [Accessed: September 17, 2014].
4. Ajani JA, D'Amico TA, Almhanna K, et al. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 1, 2015. Available at: NCCN.org. [Accessed January 22, 2015].
5. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. 7th ed. Oxford: Wiley-Blackwell; 2010.
6. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326 (24):1593-1598.
7. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Grou 94-05) phase III trial of combinedmodality therapy for esophageal cancer: highdose versus standarddose radiation therapy. J Clin Oncol. 2002;20 (5):1167-1174.
8. Gwynne S, Hurt C, Evans M, et al. Definitive chemoradiation for oesophageal cancer-A standard of care in patients with nonmetastatic oesophageal cancer. Clin Oncol (R Coll Radiol). 2011;23: 182-188.
9. Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70-75.
10. Haefner MF, Lang K, Krug D, et al. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. J Radiat Res. 2015;56:742-749.
11. Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19:2135-2141.
12. Karran A, Blake P, Chan D, et al. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg. 2014;101:502-510.
13. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168.
14. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
15. Erratum in J Clin Oncol. 2006;24:531.
16. Teoh AY, Chiu PW, Yeung WK, et al. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with respectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013;24:165-171.
17. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305e14.
18. Ruppert BN, Watkins JM, Shirai K, et al. Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010;33:346e52.
19. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in esophageal cancer patients. Ann Oncol. 2014;25:638-643.
20. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer-A meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38:599-604.
21. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084.
22. Wang DB, Zhang X, Han HL, et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: A metaanalysis. Dig Dis Sci. 2012;57:3226-3233.
23. Marriette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416-2422.
24. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545-553.
25. Chen HS, Wu SC, Hsu PK, et al. The prognostic impact of preoperative and postoperative chemoradiation in clinical stage II and III esophageal squamous cell carcinomas: A population based study in Taiwan. Medicine (Baltimore). 2015;94:e10023.
26. Wang BY, Lin PY, Wu SC, et al. Comparison of pathologic stage in patients receiving esophagectomy with and without preoperative chemoradiation therapy for esophageal SCC. J Natl Compr Canc Netw. 2014;12:1697-1705.
27. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23 2310-2317.
28. Erratum in J Clin Oncol. 2006;24:531.
29. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168.
30. Porteous GH, Neal JM, Slee A, et al. A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomes. Reg Anesth Pain Med. 2015;40 (2):139-149.
31. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16:1104-1109discussion 1110.
32. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41: 391-393.
33. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73:1779-1784.
34. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-467.
35. Erratum in N Engl J Med. 1999;341:384.
36. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
37. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
38. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15:947-954.
39. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol. 2005;6:659-668.
40. Natsugoe S, Okumura H, Matsumoto M, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006;19:468-472.
41. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-692.
42. Courrech Staal EF, Aleman BM, Boot H, et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010;97:1482-1496.
43. Wijnhoven BP, van Lanschot JJ, Tilanus HW, et al. Neoadjuvant chemoradiotherapy for esophageal cancer: A review of meta-analyses. World J Surg. 2009;33:2606-2614.
44. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
45. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327-2333.
46. Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5:229-235.
47. Bendell JC, Meluch A, Peyton J, et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol. 2012;10:430-437.
48. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 2003;21:4592-4596.
49. Teniere P, Hay JM, Fingerhut A, et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 1991;173:123-130.
50. Hsu PK, Huang CS, Wang BY, et al. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;97:1734-1741.
51. Rice TW, Adelstein DJ, Chidel MA, et al. Benet of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg. 2003;126:1590-1596.
52. Bedard ELR, Inculet RI, Malthaner RA, et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 2001;91:2423-2430.
53. Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5:244-250.
54. Javidfar J, Speicher PJ, Hartwig MG, et al. Impact of positive margins on survival in patients undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2016;101:1060-1067.
55. Wu J, Chen QX, Teng LS, et al. Prognostic significance of positive circumferential resection margin in esophageal cancer: A systematic review and meta-analysis. Ann Thorac Surg. 2014;97:446-453.